$ Value
$14.8M
Shares
443,707
Price
$33
Filed
Mar 2
Insider
Name
Davidson Michael H.
Title
Chief Executive Officer
CIK
0001573785
Roles
Transaction Details
Transaction Date
2026-03-02
Code
S
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
174,144
Footnotes
The exercise price of the option is EUR 1.16392. | The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Filing Info
Davidson Michael H.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-02 | NAMS | M | — |
| 2026-03-02 | NAMS | ▼ | $14.8M |
| 2026-03-02 | NAMS | M | $0 |
| 2026-02-26 | NAMS | M | — |
| 2026-02-26 | NAMS | ▼ | $5.6M |
| 2026-02-26 | NAMS | ▼ | $617K |
| 2026-02-26 | NAMS | M | $0 |
| 2026-02-25 | NAMS | M | — |
| 2026-02-25 | NAMS | ▼ | $1.6M |
| 2026-02-25 | NAMS | ▼ | $375K |
Other Insiders at NAMS (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Davidson Michael H.
Chief Executive Officer
|
— | $10.6M | 2026-03-02 |
|
Kastelein Johannes Jacob Pieter
Chief Scientific Officer
|
— | $1.6M | 2026-02-20 |
|
Kooij Louise Frederika
Chief Accounting Officer
|
— | $4.8M | 2026-01-28 |